Skip to content

Ketamine research published in 2018

Page 4 of 10: studies 61 to 80 of 189, newest first. Back to the ketamine overview

Studies

Cluster of acute poisonings associated with an emerging ketamine analogue, 2-oxo-PCE.

Forensic Science International September 1, 2018 Magdalene H Y Tang, Y K Chong, Candace Y Chan et al.

Ketamine and phencyclidine are well-known drugs of abuse of the arylcyclohexylamine class, the backbone of which is used for the synthesis of new psychoactive substances (NPS). In October 2017, a cluster of acute intoxications was encountered where patients presented with ketamine-like toxidrome. Upon initial toxicology screening, however, neither ketamine nor other causative agents were...

DOI: 10.1016/j.forsciint.2018.07.014 (opens in new tab) Full text (opens in new tab) 2-oxo-pce Arylcyclohexylamine Deschloro-n-ethyl-ketamine New psychoactive substance +1

Ketamine in electroconvulsive therapy for depressive disorder: A systematic review and meta-analysis.

Journal of Psychiatric Research September 1, 2018 Li Ren, Jie Deng, S. Min et al. 48 citations

Electroconvulsive therapy (ECT) is one of the most effective treatments for depressive disorder. Sub-anesthetic dose of ketamine exerts a rapid and robust antidepressive effect. However, it is still unclear whether ketamine usage in ECT is efficacious as an antidepressant. We aimed to conduct a systematic review and meta-analysis on the effects of ketamine in ECT among patients with depressive...

Comparative study of esketamine and racemic ketamine in treatment-resistant depression

Medicine September 1, 2018 Fernanda S. Correia-Melo, Gustavo C. Leal, Michelle S. Carvalho et al. 61 citations

INTRODUCTION: The use of ketamine as an option in the treatment of depressive disorder is growing rapidly, supported by numerous clinical trials attesting its efficacy and safety. Esketamine, the S (+) enantiomer of ketamine, is the most widely used form in the anesthetic environment in some countries, and new studies have shown that it may also be effective in depression and with better...

The acute and residual effects of escalating, analgesic-range doses of ketamine on driving performance: A simulator study.

Progress in Neuro-Psychopharmacology and Biological Psychiatry August 30, 2018 Amie C Hayley, Maja Green, Luke A. Downey et al.

Ketamine hydrochloride elicits potent psychotomimetic and neurobehavioural effects which make it incompatible with driving; however, the direct effect on driving performance is yet to be assessed. Using an open label, within-subjects protocol, 15 males and 5 females (mean age = 30.8 years) were administered three fixed, stepwise increasing sub-anaesthetic doses of intravenous (IV) ketamine...

Applying ketamine to alleviate the PTSD-like effects by regulating the HCN1-related BDNF.

Progress in Neuro-Psychopharmacology and Biological Psychiatry August 30, 2018 Lanwei Hou, Yirui Qi, Hongwei Sun et al.

Post-traumatic stress disorder (PTSD) is commonly associated with concurrent anxiety and depression symptoms, and reduce the expression of the Brain-Derived Neurotrophic Factor (BDNF) which promotes the proliferation and survival of neurons. The hyperpolarization-activated cyclic nucleotide-gated channel 1(HCN1) could be inhibited by the ketamine, a drug to alleviate depression and anxiety, and...

Impaired GAD1 expression in schizophrenia-related WISKET rat model with sex-dependent aggressive behavior and motivational deficit.

Genes, brain, and behavior August 29, 2018 A Büki, G Horvath, G Benedek et al.

After peri-adolescence isolation rearing (IS) and subchronic ketamine (KET) treatment, adult, selectively bred Wistar rats (named WISKET) mimic abnormal behaviors reminiscent of human schizophrenia, including reduced prepulse-inhibition of startle reflex, disturbances in cognition, locomotor activity and thermoregulation, decreased pain sensitivity and electrophysiological alterations. To...

Effect of low-dose ketamine on PerioperAtive depreSsive Symptoms in patients undergoing Intracranial tumOr resectioN (PASSION): study protocol for a randomized controlled trial.

Trials August 29, 2018 Yang Zhou, Yuming Peng, Jinghan Fang et al.

Perioperative depressive symptoms (PDS) are common mental comorbidities that influence clinical outcomes and prognosis. However, there is no rapid-acting treatment to address these symptoms during a limited hospital stay. This is a single-center, randomized, placebo-controlled, and double-blind trial. Randomization will be applied and stratified by the severity of PDS (moderate versus severe)....

DOI: 10.1186/s13063-018-2831-0 (opens in new tab) Full text (opens in new tab) Ketamine Depression symptom Perioperative Randomized controlled trial

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism

American Journal of Psychiatry August 29, 2018 Nolan Williams, Boris D. Heifets, Christine Blasey et al. 510 citations

OBJECTIVE: In addition to N-methyl-d-aspartate receptor antagonism, ketamine produces opioid system activation. The objective of this study was to determine whether opioid receptor antagonism prior to administration of intravenous ketamine attenuates its acute antidepressant or dissociative effects. METHOD: In a proposed double-blind crossover study of 30 adults with treatment-resistant...

DOI: 10.1176/appi.ajp.2018.18020138 (opens in new tab) Ketamine Antagonism Antidepressant Pharmacology +2

Syntheses of Ketamine and Related Analogues: A Mini Review

Synthesis August 20, 2018 I. Dimitrov, W. Denny, Jiney Jose

Abstract Ketamine [2-(2-chlorophenyl)-2-(methylamino)cyclohexanone] is a dissociative anaesthetic, first developed in 1963 by Parke-Davis. It finds widespread application in the treatment of battlefield injuries, and in emergency departments for use in children. In recent times the clinical interest in ketamine has increased due to the positive impact it has in treating depression and the rapid...

Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions.

Journal of Affective Disorders August 15, 2018 Patricio Riva-Posse, Collin Reiff, Johnathan A Edwards et al.

The dissociative anesthetic agent ketamine is increasingly being utilized to treat depression, despite not having FDA (Food and Drug Administration) approval for this indication. There are many questions about the potential risks of this treatment and hence the proper setting and degree of monitoring required to ensure patient safety. There is limited data about the cardiovascular safety of...

Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3β/β-catenin pathway.

Naunyn-Schmiedeberg's Archives of Pharmacology August 6, 2018 Hebatalla I Ahmed, Somaia A Abdel-Sattar, Heba S Zaky

There are increasing evidences supporting the involvement of oxidative stress and neuroinflammation in schizophrenia. Vinpocetine, a nootropic phosphodiesterase-1 inhibitor, was proven to possess anti-oxidant and anti-inflammatory potentials. This research aimed to reveal the likely protective features of vinpocetine against ketamine-induced schizophrenia-like deficits in rats. Additionally,...

Lack of antidepressant effects of low-voltage-sensitive T-type calcium channel blocker ethosuximide in a chronic social defeat stress model: Comparison with (R)-ketamine

The International Journal of Neuropsychopharmacology August 4, 2018 Z. Ryan Tian, Chao Dong, Kai Zhang et al. 18 citations

Background: A recent study demonstrated that low-voltage-sensitive T-type calcium channel blocker ethosuximide shows rapid antidepressant actions. This study was conducted to compare the antidepressant actions of ethosuximide and (R)-ketamine in a chronic social defeat stress model. Methods: Ethosuximide (100, 200, or 400 mg/kg), (R)-ketamine (10 mg/kg), or saline was administered i.p. to...

Acute ketamine dysregulates task-related gamma-band oscillations in thalamo-cortical circuits in schizophrenia.

Brain August 1, 2018 Tineke Grent-'t-Jong, Davide Rivolta, Joachim Gross et al.

Hypofunction of the N-methyl-d-aspartate receptor (NMDAR) has been implicated as a possible mechanism underlying cognitive deficits and aberrant neuronal dynamics in schizophrenia. To test this hypothesis, we first administered a sub-anaesthetic dose of S-ketamine (0.006 mg/kg/min) or saline in a single-blind crossover design in 14 participants while magnetoencephalographic data were recorded...

Prophylactic ketamine alters nucleotide and neurotransmitter metabolism in brain and plasma following stress.

Neuropsychopharmacology August 2018 Josephine C McGowan, Collin Hill, Alessia Mastrodonato et al.

Recently, we have shown that ketamine given prior to stress exposure protects against the development of depressive-like behavior in mice. These data suggest that it may be possible to prevent the induction of affective disorders before they develop by administering prophylactic pharmaceuticals, a relatively nascent and unexplored strategy for psychiatry. Here, we performed metabolomics...

Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial.

Journal of Affective Disorders August 1, 2018 Somaye Arabzadeh, Elham Hakkikazazi, Nazila Shahmansouri et al.

Major depressive disorder (MDD) exerts a high health and financial burden on society. The conventional pharmacotherapies for MDD are partially effective and the response to medication often starts with some delay. There are recent reports of antidepressant effects for oral ketamine. We employed a double-blind controlled trial to examine the time course of the therapeutic effect of ketamine when...

Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalized Anxiety and Social Anxiety.

The International Journal of Neuropsychopharmacology August 1, 2018 Shabah Mohammad Shadli, Tame Kawe, Daniel Martin et al.

Ketamine is swiftly effective in a range of neurotic disorders that are resistant to conventional antidepressant and anxiolytic drugs. The neural basis for its therapeutic action is unknown. Here we report the effects of ketamine on the EEG of patients with treatment-resistant generalized anxiety and social anxiety disorders. Twelve patients with refractory DSM-IV generalized anxiety disorder...

7T 1H-MRS in major depressive disorder: a Ketamine Treatment Study.

Neuropsychopharmacology August 2018 Jennifer W. Evans, Níall Lally, Li An et al.

The glutamatergic modulator ketamine has striking and rapid antidepressant effects in major depressive disorder (MDD), but its mechanism of action remains unknown. Proton magnetic resonance spectroscopy (1H-MRS) is the only non-invasive method able to directly measure glutamate levels in vivo; in particular, glutamate and glutamine metabolite concentrations are separable by 1H-MRS at 7T. This...

Ketamine and electroconvulsive therapy: so happy together?

Current Opinion in Anaesthesiology August 2018 Kathryn Cobb, Monika Nanda

Anesthetics, such as thiopental, methohexital, propofol and ketamine have been used to induce unconsciousness for electroconvulsive therapy (ECT), each with its advantages and disadvantages. Only until recently was it discovered that ketamine may have inherent antidepressant effects. We reviewed the side effect profile of ketamine and examined the literature for whether or not ketamine augments...

(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice.

Neuropsychopharmacology August 2018 Jun-Ichi Yamaguchi, Hidetoh Toki, Youge Qu et al.

(R,S)-Ketamine has rapid and sustained antidepressant effects in depressed patients. Although the metabolism of (R,S)-ketamine to (2 R,6 R)-hydroxynorketamine (HNK), a metabolite of (R)-ketamine, has been reported to be essential for its antidepressant effects, recent evidence suggests otherwise. The present study investigated the role of the metabolism of (R)-ketamine to (2 R,6 R)-HNK in the...

The profile of cognitive impairments in chronic ketamine users.

Psychiatry Research August 2018 Xiaoyin Ke, Yi Ding, Ke Xu et al.

The aim of this study was to examine the cognitive function in chronic ketamine users. Factors correlated to cognition impairments were analyzed. Sixty-three chronic ketamine users and 65 healthy subjects were recruited. Cognitive function was assessed by using immediate/delayed visual reproduction (IVR/DVR) tasks, immediate/delayed logical memory (ILM/DLM) tasks, Stroop test, Wisconsin card...